![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, April 27, 2004 5:16:04 PM
Panzem is in Phase II for multiple myeloma at this time. During the CC Neil mentioned that they are currently working with the FDA to get the new formulation into this trial. If this is true we won't be waiting for 2005 to see clinical results and possible fast track approval like Avastin. Genentech's drug Avastin won approval from the FDA for one application which was colorectal cancer. This was after fast track approval for the same application. Panzem only need to be approved for one application. I did hear correctly didn't I?
Dec. 7th
"Phase II data demonstrating that Panzem(R) is well tolerated and stabilized disease in patients with plateau or relapsed multiple myeloma, the second most prevalent form of blood cancer among Americans. EntreMed plans to continue evaluation in these patients using a new formulation of Panzem(R) designed to increase and prolong exposure to this drug candidate."
http://investor.entremed.com/ireye/ir_site.zhtml?ticker=ENMD&script=460&layout=-6&item_i....
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM